The new qualified slitting center in China meets the rigorous requirements of ISO 15378. The closed cleanroom environment of the slitting area is in accordance with Class D 100,000. Furthermore, the site has a fully operational micro-biological lab (environment class C 10,000), which enables quality control covering all requirements of the CFDA regulation. Several international pharmaceutical customers have visited the site to review the slitting capability, documentation and have provided extremely positive feedback, kp Pharma says.
Tracey Peacock, president-Pharmaceutical & Medical Device Films at kp, says, “We are seeing substantial growth in all product segments in Asia. New CFDA regulations in China are increasing the focus on the quality and performance of the packaging materials used, as well as increased demand for barrier performance to protect the sensitivity of new drugs. We are excited to make this first and significant step into China to support these trends in our market place.”
The new capacity will also support the Asian market as it continues to experience double-digit growth. Peacock adds, “We have been quietly adding to our capabilities in other parts of the world, and now we will accelerate actions to address the growing Asian marketplace."